

1 **Research Article**

2
3 **Pulmonary cavitation – an under-recognized late complication of severe COVID-19**
4 **lung disease**

5
6 Zaid Zoumot¹, MBBS; Maria-Fernanda Bonilla², MD; Ali S. Wahla¹, MBBS; Irfan Shafiq¹, MBBS;
7 Mateen Uzbek¹, MBBS; Rania M. El-Lababidi³, Pharm.D.; Fadi Hamed⁴, MD; Mohamed
8 Abuzakouk⁵, MBBCh; Mahmoud ElKaissi⁶, MD

9 ¹Department of Pulmonology, Respiratory Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates

10 ²Department of Infectious Diseases, Medical Specialties Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates

11 ³Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, United Arab Emirates

12 ⁴Critical Care Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates

13 ⁵Department of Allergy and Immunology, Respiratory Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates

14 ⁶Imaging Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates

15
16 **Short Title: Pulmonary Cavitation in COVID-19 Disease**

17
18 **Corresponding author:**

19 Zaid Zoumot, MBBS, PhD, FRCP

20 Department of Pulmonology, Respiratory Institute, Cleveland Clinic Abu Dhabi, P.O.Box 112412,
21 Abu Dhabi, United Arab Emirates

22 Telephone: +971 2 501 9000 Ext 46436

23 Email: zzoumot@doctors.org.uk

24 **Number of Tables:** 2

25 **Number of Figures:** 2

26 **Word Count:** 1795 (Abstract 183, Manuscript 1612)

27
28 **Keywords:** COVID-19, SARS-CoV-2, cavity, pulmonary cavitation

29 **ABSTRACT**

30 **Background:** Radiological findings of the novel coronavirus disease 2019 (COVID-19) pulmonary
31 disease have been well documented and range from scattered ground-glass infiltrates in milder
32 cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically
33 ill, however, lung cavitation has not been described in these patients.

34 **Objectives:** To assess the incidence of pulmonary cavitation and describe its characteristics and
35 evolution.

36 **Methods:** A retrospective review of all patients admitted to our institution with COVID-19 was
37 undertaken and imaging reviewed to identify patients who developed pulmonary cavitation.

38 **Results:** Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed
39 pulmonary cavitation, comprising 3.3% (n=12/359) of those with COVID-19 pneumonia, and
40 11% (n=12/110) of those admitted to the intensive care unit. We describe the imaging
41 characteristics of the cavitation and present the clinical, pharmacological, laboratory, and
42 microbiological parameters for these patients. In this cohort six patients have died while
43 another remains critically ill and unlikely to survive.

44 **Conclusion:** Cavitory lung disease in patients with severe COVID-19 disease is not uncommon,
45 and is associated with a high level of morbidity and mortality.

46

47

48

49 INTRODUCTION

50 The novel coronavirus disease 2019 (COVID-19) pandemic has caused over 500,000 recorded
51 deaths worldwide thus far[1]. Infection with the novel severe acute respiratory syndrome
52 corona virus 2 (SARS-CoV-2) causes COVID-19 which can lead to pneumonia and severe acute
53 respiratory syndrome. The typical abnormalities seen on computerized tomography (CT) of the
54 chest in patients with COVID-19 lung disease have been well described,[2–5] with a
55 comprehensive review and meta- analysis [6] of 55 studies finding peripheral ground glass
56 opacities in most, consolidation in 44% (95% CI: 1–71%), air bronchograms in 43% (95% CI: 8–
57 80%), linear opacities in 41% (95% CI: 7–65%), crazy-paving pattern in 24% (95% CI: 3–92%) and
58 interlobular septal thickening in 23% (95% CI: 1–80%) of the CT scans reviewed. Notable in this
59 meta-analysis and other studies is the absence of cavitation. Similarly, another meta-analysis of
60 15 studies including 2451 patients did not report any cavitation, but commented on the
61 development of traction bronchiectasis, consolidation, lymphadenopathy and pleural effusions
62 at late stages of severe disease[7]. Here, we present a series of 12 cases of SARS-CoV2 infection
63 that had developed cavitary lung disease while admitted to our tertiary care hospital for
64 treatment of severe COVID-19.

65

66 MATERIALS AND METHODS

67 A registry of all patients admitted to our institution with COVID-19, and approved by the
68 institution's Research Ethics Committee, was retrospectively reviewed. In total 689 patients
69 were admitted between February 23rd and July 3rd 2020, of whom 330 had asymptomatic or

70 mild disease, 359 had evidence of pneumonia and 110 were admitted to Intensive Care for
71 treatment of respiratory failure. One hundred and seventy eight patients had CT scans of the
72 chest and all patients who had cavitary lung disease on CT scan were identified. Baseline
73 demographics, comorbidities, symptoms, ventilatory and other Intensive care parameters,
74 microbiology, medications received and hospital outcomes were reviewed. Data was extracted
75 by one of three members of the research team, and verified by a second researcher. All CT
76 scans were reviewed by a single thoracic radiologist and imaging characteristics were noted.

77 In the absence of approved pharmacologic therapy for COVID-19, the Department of Infectious
78 Diseases and the antimicrobial stewardship program at our institution rapidly developed
79 institutional practice guidelines for COVID-19 based on available in-vitro and clinical studies to
80 aid clinicians with treatment decisions. These guidelines were frequently updated based on
81 emerging data. In the early stages of the pandemic asymptomatic and symptomatic patients
82 were treated with a combination of two or three medications that included
83 hydroxychloroquine, lopinavir-ritonavir and favipiravir, for a duration of 5-10 days. Tocilizumab
84 was recommended for those with evolving cytokine release storm (CRS) based on criteria that
85 encompassed clinical, radiological and laboratory parameters. One dose was initially given and
86 a second dose was optional based on the clinical evolution of the patient. Empiric antibacterial
87 and antifungal treatment was not routinely administered unless there was clinical suspicion for
88 secondary pneumonia. Amoxicillin-clavulanate and piperacillin-tazobactam were the most
89 common antibiotics used for COVID-19 patients.

91 **RESULTS**

92 Twelve patients with COVID-19 disease developed lung cavitation, comprising 1.7% (n=12/689)
93 of all admissions, 3.3% (n=12/359) of those with COVID-19 pneumonia, and 11% (n=12/110) of
94 those admitted to the ICU. Table 1 describes their baseline characteristics, clinical variables and
95 outcomes. Median (range) age was 47 (37 to 67) years, 50% (n=6/12) had diabetes mellitus,
96 42% (n=5/12) were hypertensive and one had chronic lung disease in the form of chronic
97 obstructive pulmonary disease (COPD). None had received prior immunosuppression. All 12
98 were males, required invasive mechanical ventilation, and the median (range) time from
99 symptom onset to invasive mechanical ventilation was 8 (3-15) days. Three were admitted
100 directly via our institution's Emergency Department and intubated within 24 hours, whilst the
101 other nine patients were transferred from other hospitals within 72 hours of intubation. At the
102 time of this data review six of the 12 patients had died, another remains critically ill and unlikely
103 to survive, one is still admitted having been recently decannulated off extra-corporeal
104 membrane oxygenation (ECMO) and had his tracheostomy decannulated, and four have been
105 discharged home.

106 Most patients had completed a course of Hydroxychloroquine (83 % n=10/12) and antivirals
107 (favipilavir or lopinavir/ritonavir) (92%, n=11/12) in the early stages of their illness. All 12
108 patients received Tocilizumab as clinical evidence of a CRS became apparent accompanied by
109 deteriorating respiratory status and progressively worsening disease on imaging. Overall, this
110 represented 9% (n=12/133) of patients with COVID-19 who received tocilizumab in our
111 institution.

112

113 **Imaging characteristics:**

114 Upon admission all patients had baseline chest X-rays which did not reveal any evidence of
115 cavitory disease. The 12 patients had the recognized range of imaging features expected in
116 severe COVID-19 lung disease. All had bilateral disease with ground glass opacities
117 predominantly in the peripheries some with centrally located opacities, most had consolidation
118 and air bronchograms, and roughly half had crazy paving pattern and interlobular septal
119 thickening. In 10 patients all five lobes were affected, and in two patients the disease spared
120 two lobes. The median (range) number of days between symptom onset and the first CT
121 demonstrating cavitation was 36 (21 to 54) days, and between intubation and the first CT
122 demonstrating cavitation 28 (13 to 49) days. Table 2 describes the cavities in detail. In short,
123 five of the 12 patients had solitary cavities with size ranging between 30 mm to 100 mm in
124 diameter. All patients with more than one cavity had bilateral cavitation. The appearances and
125 morphology of the cavities amongst the group were similar with to that of pulmonary abscesses
126 with thick but smooth walls containing internal debris and air fluid levels. Pulmonary infarcts
127 were excluded as the CT studies were performed with IV contrast excluding pulmonary emboli.
128 All five lobes contained cavities in a similar proportion, with a predilection for the costophrenic
129 angles and the apices.

130

131

132

133 **DISCUSSION**

134 The development of pulmonary cavitation in patients with severe COVID-19 lung disease
135 treated in our institution's ICU was not a rare event (11%, n=12/110). This subgroup of patients
136 had very severe infection with acute respiratory distress syndrome (ARDS) and required a
137 prolonged ICU stay. Median (range) Sequential Organ Failure Assessment (SOFA) score was 23
138 (range 16-24) on admission, and all patients were leucopenic. Seven of 12 required renal
139 replacement therapy, four developed venous thromboembolism, three required ECMO with
140 two surviving to successful decannulation, and two had thromboembolic cerebrovascular
141 events.

142 Cavities tended to form in areas of the lung where ground glass opacities were seen in early
143 stages, morphing into more dense consolidation, later developing necrosis and ultimately
144 cavitating. This is demonstrated for patients 8 and 9 in Figures 1 and 2, respectively. We are
145 unable to speculate as to whether bacterial infection and/or invasive fungal coinfection may
146 have contributed to the development of the cavities, or if the infections were opportunistic.
147 However it is uncommon for viral pneumonias,[8] including those due to the other human
148 coronaviruses SARS-CoV[9] and MERS-CoV,[10] to cause pulmonary cavitation even in severe
149 and advanced viral infection. Furthermore, four of twelve patients who had developed
150 pulmonary cavitation (including two of the survivors) had no microbiological, serological,
151 clinical or distinct radiological characteristics of invasive fungal infection and did not receive
152 treatment for this.

153 Four patients developed hemoptysis and all had features of suspected invasive aspergillosis.

154 Hemoptysis appeared to have occurred irrespective of cavity size. Similarly, secondary

155 pneumothorax also occurred in patients with both larger and smaller cavities.

156 All patients in this series received tocilizumab, a recombinant humanized monoclonal antibody

157 directed against both the soluble and membrane-bound forms of the interleukin-6 (IL-6)

158 receptor, in the early stages of a CRS. Tocilizumab is currently approved by the US Food and

159 Drug Administration (FDA) for the treatment of severe rheumatoid arthritis, systemic juvenile

160 idiopathic arthritis, giant cell arteritis, and life-threatening CRS induced by chimeric antigen

161 receptor T cell therapy[11]. Recently it has been associated with improved survival in patients

162 with severe COVID-19 pneumonia with evidence of CRS.[12,13] In general tocilizumab is well

163 tolerated but can induce neutropenia, and an increased risk of developing infections has been

164 reported.[14,15] Furthermore, it may predispose to a delay in detecting active infection

165 because of the masking effect of a suppressed C reactive protein (CRP) response. Interestingly,

166 however, only one of 12 patients in our cohort developed neutropenia during their ICU stay.

167 All patients in this series also received systemic glucocorticoids, which may have survival

168 benefit in COVID-19[16], but also suppress the immune system by impairing innate immunity.

169 In the treatment of patients reported here systemic steroids were administered as part of our

170 ICU protocol for septic shock, based on the Society of Critical Care Medicine guidelines[17] and

171 not directly for the treatment of their COVID-19.

172 The high level of morbidity and mortality in this small case series highlights that cavity

173 formation probably sits at the severe/end-stage of the radiological COVID-19 spectrum. It is

174 unclear what the natural history of these cavities will be in survivors. This will be informed by
175 future follow-up interval imaging but it is reasonable to assume that though there may be some
176 of regression in the size of the cavities, there will be an increased risk of pneumothorax,
177 hemoptysis, colonization with bacteria including non-tuberculous mycobacteria, fungi and the
178 development of mycetomas in the future.

179

180 **CONCLUSION**

181 This study highlights that pulmonary cavitation in patients with severe COVID-19 lung disease
182 can occur, is associated with secondary complications of hemoptysis and pneumothorax, and
183 confers a poor prognosis. Early cross sectional imaging should be considered if there is
184 suspicion of cavitation on plain radiographs, and a more aggressive investigation and treatment
185 of possible invasive fungal infection undertaken. Further studies are needed to determine
186 whether treatment with tocilizumab, systemic glucocorticoids or a combination of both may
187 increase the risk of developing pulmonary cavitation in patients with COVID-19.

188

189

190

191

192

193

194

195 **Statement of Ethics**

196 Our institution's Research Ethics Committee approved this retrospective review of an

197 authorized registry of all patients admitted with COVID-19.

198

199 **Conflict of Interest Statement**

200 The authors have no conflicts of interest to declare.

201

202 **Funding Sources**

203 There was no funding for this study.

204

205 **Author Contributions**

206 Z.Z. conceived this study, collated data and wrote the first draft of the manuscript and all

207 authors reviewed and contributed to the writing of subsequent drafts, and approved the final

208 version. M-F.B., A.S.W., I.S., M.U., and R.M.E assisted in data collection and M.E. performed the

209 imaging review, data collection and analysis.

210

211

212 **REFERENCES**

- 213 1 World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report –
214 156. Available from: Available at [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200624-covid-19-sitrep-156.pdf?sfvrsn=af42e480_2)
215 [source/coronaviruse/situation-reports/20200624-covid-19-sitrep-156.pdf?sfvrsn=af42e480_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200624-covid-19-sitrep-156.pdf?sfvrsn=af42e480_2).
- 216 2 Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging 2019 Novel Coronavirus
217 (2019-nCoV) Pneumonia. *Radiology*. 2020 Feb;295(1):210–7.
- 218 3 Kong W, Agarwal PP. Chest Imaging Appearance of COVID-19 Infection. *Radiol*
219 *Cardiothorac Imaging*. 2020 Feb;2(1):e200028.
- 220 4 Li X, Zeng X, Liu B, Yu Y. COVID-19 Infection Presenting with CT Halo Sign. *Radiol*
221 *Cardiothorac Imaging*. 2020 Feb;2(1):e200026.
- 222 5 Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019
223 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. *Am J Roentgenol*. 2020
224 Mar;215(1):87–93.
- 225 6 Zheng Y, Wang L, Ben S. Meta-analysis of chest CT features of patients with COVID-19
226 pneumonia. *J Med Virol*. n/a(n/a). DOI: 10.1002/jmv.26218
- 227 7 Sun Z, Zhang N, Li Y, Xu X. A systematic review of chest imaging findings in COVID-19.
228 *Quant Imaging Med Surg*. 2020 Apr;10(5):1058–79.
- 229 8 Koo HJ, Lim S, Choe J, Choi S-H, Sung H, Do K-H. Radiographic and CT Features of Viral
230 Pneumonia. *RadioGraphics*. 2018 May;38(3):719–39.
- 231 9 Wong KT, Antonio GE, Hui DSC, Lee N, Yuen EHY, Wu A, et al. Severe acute respiratory
232 syndrome: radiographic appearances and pattern of progression in 138 patients. *Radiology*.
233 2003 Aug;228(2):401–6.
- 234 10 Ajlan AM, Ahyad RA, Jamjoom LG, Alharthy A, Madani TA. Middle East respiratory
235 syndrome coronavirus (MERS-CoV) infection: chest CT findings. *AJR Am J Roentgenol*. 2014
236 Oct;203(4):782–7.
- 237 11 Tocilizumab (Actemra) injection, for intravenous or subcutaneous use (Genentech Inc,
238 San Francisco, CA). Prescribing Information [Internet]. [cited 2020 Jul 6]. Available from:
239 https://www.gene.com/download/pdf/actemra_prescribing.pdf
- 240 12 Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the
241 treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute
242 respiratory failure: A single center study of 100 patients in Brescia, Italy. *Autoimmun Rev*. 2020
243 Jul;19(7):102568.

- 244 13 Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab
245 in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol*. 2020
246 Jun;0(0). DOI: 10.1016/S2665-9913(20)30173-9
- 247 14 Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, et al. Risk of serious
248 infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a
249 multidatabase cohort study. *Ann Rheum Dis*. 2019;78(4):456–64.
- 250 15 Feist E, Burmester G-R. Is tocilizumab in combination with traditional DMARDs safe and
251 effective for patients with active RA? *Nat Clin Pract Rheumatol*. 2009 Mar;5(3):128–9.
- 252 16 Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone
253 in Hospitalized Patients with COVID-19: Preliminary Report. *medRxiv*. 2020
254 Jun;2020.06.22.20137273.
- 255 17 Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis
256 Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Crit Care*
257 *Med*. 2017 Mar;45(3):486–552.
- 258
- 259
- 260
- 261

TABLE LEGENDS

Table 1: Patient characteristics and outcomes of those who developed pulmonary cavitation.

Table 2: Characteristics of the pulmonary cavities and related events.

FIGURE LEGENDS

Fig. 1: Axial and coronal CT images at from patient 8 on (A) 5th May 2020, (B) 26th May 2020, and (C) 6th June 2020.

Fig. 2: Axial and coronal CT images at from patient 9 on (A) 14th May 2020, (B) 8th June 2020, and (C) 18th June 2020.

Table 1: Patient characteristics and outcomes of those who developed pulmonary cavitation.

| | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 |
|---|-----------|------------|-----------|-----------|-----------|-----------|---------------------|-------------------|-----------------|-----------------|-----------------|-----------------|
| Age | 54 | 44 | 67 | 49 | 60 | 51 | 42 | 38 | 42 | 50 | 36 | 42 |
| BMI | 30.9 | 30.4 | 31.3 | 29.2 | 25.1 | 29.4 | 26.3 | 21.5 | 30.1 | 19.8 | 24 | 27.7 |
| Comorbidities | DM, HT | HT | DM | DM | COPD | HT | HT | | DM, HT | DM | DM | DM |
| On admission | | | | | | | | | | | | |
| Time from symptom onset to intubation (days) | 6 | 12 | 9 | 7 | 5 | 5 | 8 | 15 | 3 | 9 | 10 | 8 |
| P/F ratio | 48.8 | 41.6 | 49.7 | 33.0 | 46.1 | 47.0 | 65.3 | 41.8 | 70.5 | 100.1 | 109.4 | 104.5 |
| SOFA score (points) | 24 | 21 | 24 | 25 | 23 | 23 | 16 | 21 | 25 | 23 | 18 | 17 |
| Neutropenia | | | | | | | | | | | Y | |
| Leucocytes (x10⁹/L) | 0.49 | 1.35 | 0.3 | 2.78 | 0.6 | 1.1 | 1.66 | 1.03 | 0.46 | 2.91 | 1.62 | 2.63 |
| During admission | | | | | | | | | | | | |
| NM blockade | Y | Y | Y | Y | Y | Y | Y | Y | Y | | | Y |
| VTE | | DVT and PE | | | | PE | DVT | | | DVT | | |
| CVA | Y | | | | | | | | | Y | | |
| CRRT/IHD | | Y | Y | Y | Y | Y | | | Y | | | Y |
| ECMO | | | | | | | Y | Y | Y | | | |
| Proned | Y | Y | Y | Y | Y | Y | | Y | Y | Y | | |
| Tracheostomy | Y | | Y | Y | Y | Y | Y | Y | Y | | | |
| Days of systemic CS | 17 | 15 | 19 | 24 | 11 | 14 | 14 | 25 | 18 | 9 | 6 | 5 |
| +ve fungal cultures or serology | | Y | Y | Y | | Y | | | Y | | | |
| Treated for fungal infection | Y | Y | Y | Y | | Y | Y | | Y | | | Y |
| Duration of hospital stay (days) | 37 | 25 | 53 | 33 | 53 | 74 | 56 | 57 | 57 | 56 | 47 | 40 |
| Outcome | | | | | | | | | | | | |
| | Deceased | Deceased | Deceased | Deceased | Deceased | Deceased | Unlikely to survive | Likely to survive | Discharged home | Discharged home | Discharged home | Discharged home |

BMI= Body Mass Index, P/F ratio = PaO₂/FiO₂, SOFA = Sequential Organ Failure Assessment, NM = neuromuscular, Y=yes, VTE = venous thromboembolism, DVT= deep vein thrombosis, PE=pulmonary embolus, CVA = cerebrovascular accident, CRRT = continuous renal replacement therapy, IHD = intermittent hemodialysis, ECMO = extracorporeal membrane oxygenation, CS= corticosteroids

Table 2: Characteristics of the pulmonary cavities and related events.

| | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 |
|--|----------------------|------------|-------------|-----------|----------------------------------|-----------------------------|---|----------------------|----------------------------|---------------------------------|-------------|----------------------|
| No. of Cavities (n) | 1 | 8 | 8 | 3 | 1 | 1 | 2 | 1 | 9 | 3 | 1 | 5 |
| Largest Cavity (mm) | 50 | 85 | 60 | 30 | 30 | 30 | 70 | 100 | 54 | 52 | 50 | 40 |
| Bilateral | | Y | Y | Y | | | Y | | Y | Y | | Y |
| Location of Cavities | | | | | | | | | | | | |
| No. lobes with cavities (n) | 1 | 5 | 5 | 3 | 1 | 4 | 2 | 1 | 4 | 3 | 1 | 3 |
| RUL | | Y | Y | Y | | | | Y | Y | Y | Y | |
| RML | | Y | Y | | Y | Y | | | Y | | | |
| RLL | | Y | Y | | | Y | Y | | Y | Y | | Y |
| LUL | | Y | Y | Y | | Y | Y | | Y | | | Y |
| LLL | Y | Y | Y | Y | | Y | | | | Y | | Y |
| Clinical Events | | | | | | | | | | | | |
| Developed Pneumothorax | | | | Y | | | | Y | Y | | | Y |
| Developed Hemoptysis | | | Y | | | | Y | | Y | | | Y |
| Treated for Invasive fungal infection | Y | Y | Y | Y | | Y | Y | | Y | | | Y |
| Bacterial organisms in Sputum/BAL | <i>K. pneumoniae</i> | <i>ECC</i> | <i>MRSA</i> | | <i>S. maltophilia, C. koseri</i> | <i>MSSA, S. maltophilia</i> | <i>S. marcescens, S. maltophilia, ECC</i> | <i>K. pneumoniae</i> | <i>Acinetobacter, MRSA</i> | <i>ESBL K. pneumoniae, MRSA</i> | <i>MRSA</i> | <i>K. pneumoniae</i> |

Y= Yes, RUL = Right upper lobe, RML = Right middle lobe, RLL = Right lower lobe, LUL = Left upper lobe, LLL = Left lower lobe, BAL = Bronchoalveolar Lavage, MRSA = Methicillin-resistant Staphylococcus aureus, MSSA = Methicillin-sensitive Staphylococcus aureus, K. pneumoniae = Klebsiella pneumonia, ECC = Enterobacter cloacae complex, S. maltophilia = Stenotrophomonas maltophilia, S. marcescens = Serratia marcescens, ESBL = Extended spectrum beta-lactamase



